Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
To own Oscar Health today, you need to believe its technology, pricing discipline, and ACA-focused model can sustain profitable growth while keeping medical costs under control. The key near term catalyst is whether the company can deliver on its sharply higher 2026 operating earnings guidance, while the biggest current risk is that utilization, risk adjustment, or churn pressures could erode margins again. The latest results and guidance upgrade directly sharpen both the opportunity and that risk.
The most relevant update is Oscar Health’s decision on 6 August 2026 to nearly double its 2026 earnings from operations guidance to US$500–US$700 million, while reaffirming revenue of US$18.7–US$19.0 billion. For anyone watching catalysts, this raises the bar for execution on pricing, cost control, and membership quality, making each upcoming quarter a more important test of whether the recent profitability can hold up under real world medical cost trends.
Yet against this stronger outlook, the risk that medical costs, risk adjustment, and churn could again pressure margins is something investors should be aware of as they consider...
Read the full narrative on Oscar Health (it's free!)
Oscar Health's narrative projects $23.8 billion revenue and $998.5 million earnings by 2029. This requires 21.4% yearly revenue growth and about a $1.0 billion earnings increase from -$39.4 million today.
Uncover how Oscar Health's forecasts yield a $24.20 fair value, a 26% downside to its current price.
Some of the lowest ranked analysts were already cautious, assuming only about US$18.9 billion of revenue and US$813.7 million of earnings by 2029, so this latest profitability surprise may force a rethink of both their downside risks and upside catalysts.
Explore 8 other fair value estimates on Oscar Health - why the stock might be a potential multi-bagger!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com